ArticleTrials2026
Effects of chitosan supplementation versus placebo on liver fat and metabolic parameters in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of SPISE with prevalent and incident MASLD: a two-stage population-based study and development of a risk prediction model.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) is a common chronic liver disorder affecting about one-third of the global population. It encompasses a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) and may progress to fibrosis and cirrhosis. Chitosan oligosaccharide (COS) has recently emerged as a potential therapeutic agent with antioxidant and anti-inflammatory properties; however, most evidence comes from animal studies. Further clinical research is therefore warranted to evaluate its efficacy in humans.
methodThis double-blind, randomized, placebo-controlled phase II clinical trial will evaluate the effects of chitosan supplementation in patients with hepatic steatosis. Sixty eligible adults diagnosed by elastography will be recruited from the gastroenterology and liver clinic at Imam Reza Hospital, Mashhad, Iran. Participants will be randomly assigned to receive either 1.5 g/day of chitosan (500 mg capsules, taken three times daily after meals) or a matching placebo for eight weeks. All participants will receive standardized dietary counseling. Primary outcomes include changes in liver fat content measured by elastography at baseline and week 8. Secondary outcomes include alterations in anthropometric measures, liver enzymes, fasting glucose, lipid profile, and insulin resistance.
conclusionBased on animal evidence, chitosan supplementation is expected to reduce hepatic fat accumulation, improve liver enzyme levels, and enhance metabolic parameters in patients with NAFLD. If confirmed, these findings could support the potential of chitosan as a promising adjunct for managing hepatic steatosis.
trial registrationThis study is registered on the Iranian Registry of Clinical Trials (IRCT20230522058260N1: https://www.irct.ir/trial/79063 ) and first release date of 8th March 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.